Akari Therapeutics PLC
AKTX0.267USD
+0.022+8.93%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.71MMarket Cap
LossP/E TTM
More Details of Akari Therapeutics PLC Company
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Akari Therapeutics PLC Info
Ticker SymbolAKTX
Company nameAkari Therapeutics PLC
IPO dateJan 31, 2014
CEOGaslightwala (Abizer)
Number of employees8
Security typeDepository Receipt
Fiscal year-endJan 31
Address401 East Jackson Street
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33602
Phone19292747510
Websitehttps://www.akaritx.com/
Ticker SymbolAKTX
IPO dateJan 31, 2014
CEOGaslightwala (Abizer)
Company Executives of Akari Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.70M
+23.48%
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.46M
+22.20%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
262.71K
+8.69%
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Interim Chief Financial Officer
Interim Chief Financial Officer
64.90K
+933.87%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
44.64K
--
Mr. Sandip I Patel, J.D.
Mr. Sandip I Patel, J.D.
Independent Director
Independent Director
--
--
Mr. James Neal
Mr. James Neal
Independent Director
Independent Director
--
--
Dr. Samir R. Patel, M.D.
Dr. Samir R. Patel, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.70M
+23.48%
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.46M
+22.20%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
262.71K
+8.69%
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Interim Chief Financial Officer
Interim Chief Financial Officer
64.90K
+933.87%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
44.64K
--
Mr. Sandip I Patel, J.D.
Mr. Sandip I Patel, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Huh (Hoyoung)
10.26%
Patel (Samir Rashmikant)
5.82%
Prudo-Chlebosz (Raymond)
5.37%
Theofilos (Charles Steve)
2.32%
Cresset Asset Management, LLC
1.80%
Other
74.44%
Shareholders
Shareholders
Proportion
Huh (Hoyoung)
10.26%
Patel (Samir Rashmikant)
5.82%
Prudo-Chlebosz (Raymond)
5.37%
Theofilos (Charles Steve)
2.32%
Cresset Asset Management, LLC
1.80%
Other
74.44%
Shareholder Types
Shareholders
Proportion
Individual Investor
24.57%
Investment Advisor/Hedge Fund
1.80%
Hedge Fund
0.45%
Investment Advisor
0.39%
Research Firm
0.05%
Other
72.73%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
28
1.18M
1.76%
--
2025Q3
29
1.18M
1.99%
+619.33K
2025Q2
32
562.62K
1.32%
+246.34K
2025Q1
30
316.27K
1.68%
-168.17K
2024Q4
30
334.66K
1.81%
+141.56K
2024Q3
26
196.35K
3.85%
+1.13K
2024Q2
27
181.71K
3.36%
-654.00
2024Q1
27
182.37K
4.59%
-184.03K
2023Q4
27
127.87K
7.93%
-179.37K
2023Q3
27
307.25K
13.63%
-202.69K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Huh (Hoyoung)
4.70M
14.4%
+892.86K
+23.48%
Mar 06, 2025
Patel (Samir Rashmikant)
2.66M
8.17%
+957.65K
+56.14%
Nov 14, 2024
Prudo-Chlebosz (Raymond)
2.46M
7.53%
+446.43K
+22.20%
Mar 06, 2025
Theofilos (Charles Steve)
1.06M
3.25%
+1.06M
--
May 31, 2024
Cresset Asset Management, LLC
18.41K
0.06%
--
--
Jun 30, 2025
Gaslightwala (Abizer)
262.71K
0.81%
+21.00K
+8.69%
Aug 25, 2025
Palo Alto Investors LP
146.02K
0.45%
--
--
Jun 30, 2025
Hightower Advisors, LLC
79.24K
0.24%
+79.24K
--
Jun 30, 2025
Bazemore (Robert B)
44.64K
0.14%
+44.64K
--
Mar 06, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
Date
Type
Ratio
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
Aug 15, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Akari Therapeutics PLC?
The top five shareholders of Akari Therapeutics PLC are:
Huh (Hoyoung) holds 4.70M shares, accounting for 14.40% of the total shares.
Patel (Samir Rashmikant) holds 2.66M shares, accounting for 8.17% of the total shares.
Prudo-Chlebosz (Raymond) holds 2.46M shares, accounting for 7.53% of the total shares.
Theofilos (Charles Steve) holds 1.06M shares, accounting for 3.25% of the total shares.
Cresset Asset Management, LLC holds 18.41K shares, accounting for 0.06% of the total shares.
Huh (Hoyoung) holds 4.70M shares, accounting for 14.40% of the total shares.
Patel (Samir Rashmikant) holds 2.66M shares, accounting for 8.17% of the total shares.
Prudo-Chlebosz (Raymond) holds 2.46M shares, accounting for 7.53% of the total shares.
Theofilos (Charles Steve) holds 1.06M shares, accounting for 3.25% of the total shares.
Cresset Asset Management, LLC holds 18.41K shares, accounting for 0.06% of the total shares.
What are the top three shareholder types of Akari Therapeutics PLC?
The top three shareholder types of Akari Therapeutics PLC are:
Huh (Hoyoung)
Patel (Samir Rashmikant)
Prudo-Chlebosz (Raymond)
Huh (Hoyoung)
Patel (Samir Rashmikant)
Prudo-Chlebosz (Raymond)
How many institutions hold shares of Akari Therapeutics PLC (AKTX)?
As of 2025Q4, 28 institutions hold shares of Akari Therapeutics PLC, with a combined market value of approximately 1.18M, accounting for 1.76% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.24%.
What is the biggest source of revenue for Akari Therapeutics PLC?
In --, the -- business generated the highest revenue for Akari Therapeutics PLC, amounting to -- and accounting for --% of total revenue.
